Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | February 01, 2018 | February 05, 2018 |
| Medpace Holdings, Inc.MEDP · Entity 3327 | Director · President & CEO · 10% owner | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 20,000 |
Reported balance
After 2018-02-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-01 · Grant · Acquired 20,000 · Balance 20,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 29,994 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,994 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 1,642,492 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,642,492 F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 268,428 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 268,428 F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.
F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Medpace Holdings, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 338,225 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Sale · Disposed 26,701 · Balance 360,191 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Row 2 · 2026-09-30 · Sale · Disposed 21,966 · Balance 338,225 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Medpace Investors, LLC | 4,733,019 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,733,019 F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 23, 2021 Filed Nov 24, 2021 19:46 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 26,057 | $212.64 | $5,540,760.48 |
DisclosureSEC source: 0001567619-21-021146 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,883,017 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $221.11. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 19:46 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 48,128 | $224.33 | $10,796,554.24 |
DisclosureSEC source: 0001567619-21-021146 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,909,074 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $219.65 to $229.19. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:25 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 604 | $191.82 | $115,859.28 |
DisclosureSEC source: 0001567619-21-016792 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,957,202 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $190.76 to $192.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:25 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 30,234 | $191.85 | $5,800,392.90 |
DisclosureSEC source: 0001567619-21-016792 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,957,806 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $186.49 to $194.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:04 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 14,304 | $186.29 | $2,664,692.16 |
DisclosureSEC source: 0001567619-21-016650 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,988,040 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.575 to $187.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:04 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,675 | $182.04 | $2,307,357.00 |
DisclosureSEC source: 0001567619-21-016650 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,002,344 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.82 to $185.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,236 | $183.14 | $2,240,901.04 |
DisclosureSEC source: 0001567619-21-016509 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,015,019 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.57 to $184.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 11,840 | $181.83 | $2,152,867.20 |
DisclosureSEC source: 0001567619-21-016509 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,027,255 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.4175 to $183.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 466 | $180.17 | $83,959.22 |
DisclosureSEC source: 0001567619-21-016406 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,039,095 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.59. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,622 | $180.54 | $1,376,075.88 |
DisclosureSEC source: 0001567619-21-016406 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,039,561 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,814 | $180.06 | $326,628.84 |
DisclosureSEC source: 0001567619-21-016330 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,047,183 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.37. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,482 | $180.22 | $267,086.04 |
DisclosureSEC source: 0001567619-21-016330 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,048,997 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.94. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 2,301 | $180.49 | $415,307.49 |
DisclosureSEC source: 0001567619-21-016174 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,050,479 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.40. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,246 | $182.10 | $955,296.60 |
DisclosureSEC source: 0001567619-21-016057 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,052,780 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $184.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 16,817 | $182.83 | $3,074,652.11 |
DisclosureSEC source: 0001567619-21-016057 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,058,026 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $185.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:25 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 556 | $180.04 | $100,102.24 |
DisclosureSEC source: 0001567619-21-014739 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,074,843 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.10. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 131 | $180.93 | $23,701.83 |
DisclosureSEC source: 0001567619-21-014098 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,075,399 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,209 | $181.47 | $2,759,977.23 |
DisclosureSEC source: 0001567619-21-014098 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,075,530 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 18,882 | $181.21 | $3,421,607.22 |
DisclosureSEC source: 0001567619-21-013970 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,090,739 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.33. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,516 | $180.63 | $1,538,245.08 |
DisclosureSEC source: 0001567619-21-013970 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,109,621 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.89. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 9,206 | $182.42 | $1,679,358.52 |
DisclosureSEC source: 0001567619-21-013843 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,118,137 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.325 to $184.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 10,176 | $183.06 | $1,862,818.56 |
DisclosureSEC source: 0001567619-21-013843 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,127,343 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $184.45. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,442 | $181.11 | $261,160.62 |
DisclosureSEC source: 0001567619-21-013714 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,137,519 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.235. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,454 | $182.83 | $2,276,964.82 |
DisclosureSEC source: 0001567619-21-013714 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,138,961 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.605 to $184.48. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 13,697 | $181.88 | $2,491,210.36 |
DisclosureSEC source: 0001567619-21-013571 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,151,415 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.38 to $183.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 11,026 | $182.63 | $2,013,678.38 |
DisclosureSEC source: 0001567619-21-013571 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,165,112 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.655 to $184.18. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 13,050 | $182.96 | $2,387,628.00 |
DisclosureSEC source: 0001567619-21-013375 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,176,138 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.325 to $184.59. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 10,540 | $183.22 | $1,931,138.80 |
DisclosureSEC source: 0001567619-21-013375 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,189,188 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.715 to $184.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:19 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,597 | $183.34 | $2,309,533.98 |
DisclosureSEC source: 0001567619-21-013235 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,199,728 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.595 to $184.98. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:19 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,951 | $180.18 | $711,891.18 |
DisclosureSEC source: 0001567619-21-013235 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,212,325 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.72. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,574 | $180.33 | $824,829.42 |
DisclosureSEC source: 0001567619-21-013138 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,216,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.905. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,729 | $180.58 | $853,962.82 |
DisclosureSEC source: 0001567619-21-013138 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,220,850 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.28. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,556 | $180.16 | $640,648.96 |
DisclosureSEC source: 0001567619-21-013007 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,225,579 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 238 | $180.03 | $42,847.14 |
DisclosureSEC source: 0001567619-21-013007 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,229,135 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $180.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,926 | $181.11 | $892,147.86 |
DisclosureSEC source: 0001567619-21-012835 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,229,373 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.395. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,225 | $181.15 | $1,489,958.75 |
DisclosureSEC source: 0001567619-21-012697 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,234,299 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.265. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 10,846 | $180.56 | $1,958,353.76 |
DisclosureSEC source: 0001567619-21-012697 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,242,524 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.505. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,837 | $180.79 | $332,111.23 |
DisclosureSEC source: 0001567619-21-012618 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,253,370 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,133 | $182.31 | $2,211,967.23 |
DisclosureSEC source: 0001567619-21-012513 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,255,207 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $181.21 to $183.99. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 9,345 | $181.86 | $1,699,481.70 |
DisclosureSEC source: 0001567619-21-012513 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,267,340 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.035 to $182.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,261 | $180.43 | $227,522.23 |
DisclosureSEC source: 0001567619-21-012434 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,276,685 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $181.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,927 | $181.20 | $1,617,572.40 |
DisclosureSEC source: 0001567619-21-012434 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,277,946 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.405. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 17,413 | $181.13 | $3,154,016.69 |
DisclosureSEC source: 0001567619-21-012320 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,286,873 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $182.685. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,706 | $182.00 | $2,858,492.00 |
DisclosureSEC source: 0001567619-21-012320 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,304,286 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $183.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:06 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantEmployee Stock Option (Right to Buy) · Derivative | 57,570 | $0.00 Strike: $166.73 | $0.00 |
DisclosureSEC source: 0001567619-21-008746 · doc1.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,570 Underlying: Common Stock · 57,570 shares Expires 2029-04-27 F2 · derivative.exercise_date: The Option vests on April 27, 2023, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 20:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 20,729 | $193.38 | $4,008,574.02 |
DisclosureSEC source: 0001567619-21-008643 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,319,992 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $188.54 to $195.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,805 | $190.51 | $1,486,930.55 |
DisclosureSEC source: 0001567619-21-008643 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,340,721 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $187.515 to $191.705. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 20:20 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 14,377 | $188.64 | $2,712,077.28 |
DisclosureSEC source: 0001567619-21-008540 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,348,526 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $185.25 to $191.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:20 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,687 | $187.02 | $2,933,782.74 |
DisclosureSEC source: 0001567619-21-008540 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,362,903 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $182.95 to $189.39. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 21, 2021 20:09 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 17,623 | $182.44 | $3,215,140.12 |
DisclosureSEC source: 0001567619-21-008413 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,378,590 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $180.00 to $185.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.